Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
The hirsute woman: Challenges in evaluation and management
Rodis Paparodis
,
Andrea Dunaif
Research output
:
Contribution to journal
›
Review article
›
peer-review
27
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The hirsute woman: Challenges in evaluation and management'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
17-hydroxyprogesterone (17-OHP)
9%
Active Metabolite
9%
Alternative Therapy
9%
Androgen Action
9%
Androgen Receptor
9%
Androgen-independent
9%
Antiandrogen
9%
Clinical Course
9%
Clinical Problems
9%
Cyproterone Acetate
9%
Dehydroepiandrosterone Sulfate (DHEAS)
9%
Diagnostic Approach
9%
Diagnostic Management
9%
Dihydrotestosterone
9%
Early Morning
9%
Etiology
9%
Finasteride
9%
Flutamide
9%
Follicular Phase
9%
Hair Growth
9%
Hirsutism
100%
Metformin
18%
Metformin Use
9%
Monotherapy
9%
Oral Contraceptives
36%
Phase Measurement
9%
Pilosebaceous Unit
9%
Polycystic Ovary Syndrome
9%
Postmenopausal Women
9%
Prolactin
9%
Reductase Activity
9%
Sex Hormone-binding Globulin
9%
Spironolactone
18%
Teratogenicity
9%
Terminal Hair
9%
Testosterone
27%
Thyrotropin
9%
Total Testosterone
9%
Treatment Options
9%
United States
9%
Women Challenges
100%
Medicine and Dentistry
Active Metabolite
9%
Androgen
18%
Androgen Receptor
9%
Androstanolone
9%
Antiandrogen
9%
Bioavailability
9%
Cyproterone Acetate
9%
Disease
9%
Disease Course
9%
Flutamide
9%
Follicular Phase
9%
Glucocorticoid
9%
Glycon
27%
Hirsutism
100%
Hydroxyprogesterone
9%
Laboratory Test
9%
Monotherapy
9%
Oral Contraceptive
9%
Oral Contraceptive Agent
27%
Oxidoreductase
9%
Physical Examination
18%
Pilus
9%
Polycystic Ovary Syndrome
9%
Prasterone Sulfate
9%
Premenopause
9%
Prolactin
9%
Sex Hormone Binding Globulin
9%
Spironolactone
18%
Target Tissue
9%
Teratogenicity
9%
Thyrotropin
9%
Treatment Option
9%
Pharmacology, Toxicology and Pharmaceutical Science
Active Metabolite
9%
Androgen
18%
Androgen Receptor
9%
Androstanolone
9%
Antiandrogen
9%
Bioavailability
9%
Cyproterone Acetate
9%
Dehydroepiandrosterone Sulfate
9%
Disease Course
9%
Finasteride
9%
Flutamide
9%
Glucocorticoid
9%
Hirsutism
100%
Hydroxyprogesterone
9%
Metformin
27%
Monotherapy
9%
Oral Contraceptive
9%
Oral Contraceptive Agent
27%
Ovary Polycystic Disease
9%
Oxidoreductase
9%
Prolactin
9%
Sex Hormone Binding Globulin
9%
Spironolactone
18%
Teratogenicity
9%
Thyrotropin
9%